Biodistribution of 99mTc-PLA/PVA/Atezolizumab nanoparticles for non-small cell lung cancer diagnosis
Makaleler > Tam Makale · 2022
Yazarlar: Meliha EKİNCİ, RALPH SANTOS-OLİVEİRA, Derya İLEM ÖZDEMİR
European Journal of Pharmaceutics and Biopharmaceutics, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2022, cilt 176, ss 21-31
DOI: 10.1016/j.ejpb.2022.05.006
Özet
<p>Lung cancer (LC) is a common type of cancer, which is a leading cause of death around the world. There is an urgency for the development of new drugs that could diagnose the LC in the early stages and in a precise manner. In this direction, the development of <a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/nanoparticle" rel="noopener noreferrer" target="_blank">nanoparticles</a> radiolabeled with the diagnostic <a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/radioisotope" rel="noopener noreferrer" target="_blank">radioisotopes</a> represent an important advance in the field of cancer imaging. In this study were developed PLA/PVA/Atezolizumab nanoparticles which were radiolabeled with 99mTc (Technetium-99m). The radiolabeled nanoparticles were evaluated in both: <em>in-vitro</em> (<em>L-929</em> and <em>A-549</em>) as <em>in-vivo</em> (mice). The results showed no cytotoxicity effect in the healthy cells (<em>L-929</em>) and cytotoxicity effect in the tumor cells (<em>A-549</em>). The <a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/biodistribution" rel="noopener noreferrer" target="_blank">biodistribution</a> assay demonstrated that 99mTc-PLA/PVA/Atezolizumab could reach the tumor site 14-folds higher than the nonparticulate atezolizumab. In conclusion, 99mTc-PLA/PVA/Atezolizumab nanoparticles showed to be a new drug which is able to precisely image the lung tumor, and it must be considered for clinical trials.</p>